Pluristem Signs MOU With Fukushima Medical University To Study PLX-R18 In ARS

(RTTNews) - Pluristem Therapeutics Inc. (PSTI) said it has signed a Memorandum of Understanding for a collaboration with Fukushima Medical University, Fukushima Global Medical Science Center.

The collaboration is to develop Pluristem's PLX-R18 cells for the treatment of Acute Radiation Syndrome or ARS, and for morbidities following radiotherapy in cancer patients.

ARS is caused by exposure to dangerously high levels of radiation and incorporates potentially lethal damage to the gastrointestinal tract, lung, skin and bone marrow, as well as other systems.

In the collaboration, PLX-R18 cells will be studied primarily as a potential treatment for radiation-induced damage to the skin, lungs and gastrointestinal tract.

The parties intend to develop preclinical models of radiation damage in these tissues, and then use them in trials.

Pluristem will contribute PLX-R18 cells and scientific knowledge, while Fukushima Medical University will conduct the studies, and provide the required resources.